Amgen's Subcutaneous Tepezza Achieves Positive Phase 3 Results in Thyroid Eye Disease
AMGN sits 33% above its 52-week low of $261.43.
Summary
Amgen announced positive topline Phase 3 results for its subcutaneous formulation of Tepezza in adults with moderate-to-severe active Thyroid Eye Disease. The OBI trial successfully met its primary and key secondary endpoints, demonstrating a clinically meaningful reduction in proptosis, with overall safety results generally consistent with the known intravenous formulation. This development is significant as Tepezza is an established drug, and a subcutaneous version offers enhanced patient convenience, potentially broadening its market reach and strengthening Amgen's position in the Thyroid Eye Disease treatment landscape. This positive pipeline news follows other recent developments for Amgen, including positive Repatha trial results, and will likely be viewed favorably by investors. The market will now anticipate full data disclosure and regulatory submission plans.
At the time of this announcement, AMGN was trading at $346.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $187.6B. The 52-week trading range was $261.43 to $391.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.